Strategy

Olympia Pharmaceutical’s CEO discusses the company’s expansion into Mississippi.

Metsera finalizes a $10 billion merger with Pfizer after rejecting Novo Nordisk's bids amid legal concerns to ensure shareholder value and regulatory safety.

As the three models converge, expect a bigger role for sales reps, minimal impact on incentive compensation, and a boon to the healthcare system.

The formula for bridging scientific advancement with operational flexibility in boosting access to cell and gene therapies.

Novo Nordisk proposes a $9 billion acquisition of Metsera, prompting responses from both Metsera and Pfizer amid ongoing merger discussions.

Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.

Galapagos scales back its cell therapy business to enhance efficiency and focus on transformative opportunities, impacting over 365 employees globally.

A case study in leading and guiding a cultural reset and strategic revival.

With ever-increasing costs to put a single molecule on the market, the pressure to reach clinical milestones quickly and efficiently often drives a focus on short-term gains that can create significant long-term liabilities, jeopardizing the path to commercial viability.

The key steps for pharma in pivoting from proof-of-concept experimenting to enterprise-scale value.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition journey.

Useful tips and parallels for staying in the game following a complete response letter.

Executives are exploring various strategies to prepare for an uncertain pricing environment in the coming months and years.

Ken Banta, founder and CEO of The Vanguard Network, reveals the mindsets and moves biopharma leaders need to not just endure—but rise above—the current age of industry disruption.

Despite steady innovation and solid new drug approvals, the first half of 2025 was marked by a break from historical norms in financing, stock performance, and M&A for the pharma and biotech sectors.

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative pricing strategies.

Access inequity is a multitude of smaller, interconnected operational and bureaucratic challenges.

The Regeneron litigation highlights that donations routed through independent entities are not immune from challenge, especially if the government believes they are effectively covering a patient’s co-pay for a specific product.

The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.

In many plants, the full expression of therapeutic value only emerges when their components are allowed to work in concert.

The regulatory environment has become increasingly supportive of multi-indication development.

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

Both community and academic delivery models play essential and complementary roles in expanding CGT access.